Novartis, CH0012005267

Novartis stock gets a USD 575 million mRNA deal

Published on 10/05/2026 at 17:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock was last at CHF 116.18 on October 5, 2026, after a USD 575 million mRNA licensing deal. Q2 sales rose 3 percent in USD terms.

Futuristisches Forschungsgebäude mit ovaler Glasfassade und Spiegelteich im Vordergrund — Novartis AG CH0012005267 – Futuristisches Forschungsgebäude mit ovaler Glasfassade, Spiegelteich und Grünanlagen, Illustration mit AI erstellt.

Novartis stock (ISIN CH0012005267) was last at CHF 116.18 on the SIX Swiss Exchange on October 5, 2026, down 0.14 percent during the session. The company is also entering an mRNA licensing agreement with an upfront payment of USD 575 million, putting pipeline development back at the center of the investment debate.

USD 575 million upfront deal

According to NovaPharma News on October 2, 2026, Novartis agreed to pay USD 575 million upfront for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune disease. Further milestone payments can reach USD 7.2 billion if Novartis exercises the available options and development, regulatory and commercial targets are met.

The transaction expands Novartis' immunology pipeline, but the payment structure matters. The USD 575 million is the upfront amount, while the USD 7.2 billion represents a contingent ceiling rather than a guaranteed cash outflow. The agreement remains subject to customary closing conditions, including regulatory clearances.

Q2 growth meets generic pressure

In Q2 2026, Novartis generated USD 14.41 billion in net sales, up 3 percent in US dollars and 1 percent at constant exchange rates, according to InvestorsHub. Net income fell 19 percent to USD 3.26 billion, while the core operating margin was 41.2 percent.

The contrast is central to the stock story: newer products are supporting sales growth, but generic competition and pipeline setbacks continue to pressure profitability. Novartis reaffirmed its 2026 outlook for low single-digit sales growth and a low single-digit decline in core operating income at constant exchange rates, as reported in the company's Q2 2026 newsroom release.

Analysts keep a Hold view

MarketBeat reported a Hold consensus from 20 analysts, with an average twelve-month price target of USD 148.40, a high of USD 180.00 and a low of USD 126.00. The consensus target is 5.27 percent above the USD 140.97 reference price used by MarketBeat on October 2, 2026.

The market signal is more restrained on the Swiss listing. Novartis stock has gained 6.15 percent year to date, while its one-year range stands at CHF 97.05 to CHF 132.68, according to the SIX quote data reported by Finanz und Wirtschaft. At CHF 116.18, the share is 12.4 percent below that one-year high, leaving the pipeline update as a test of whether future growth can offset generic erosion.

Novartis stock stays below its yearly high

Novartis stock was last at CHF 116.18 on the SIX Swiss Exchange on October 5, 2026, with session volume of 1,358,921 shares. The next scheduled company event is the Q3 2026 financial results on October 27, 2026.